古塞奇尤单抗注射液治疗其他生物制剂应答不佳的中重度斑块状银屑病的疗效及安全性
Efficacy and safety of guselkumab in treating moderate-to-severe plaque psoriasis with inadequate response to other biologics
张奕雯 1杜纳 1杨婧怡 1吕心妍 1汪艺晞 1闵玮1
作者信息
- 1. 215000 苏州,苏州大学附属第一医院皮肤科
- 折叠
摘要
目的 评估古塞奇尤单抗注射液治疗其他生物制剂应答不佳的中重度斑块状银屑病患者的疗效及安全性.方法 纳入14例患者,其中男9例,女5例,年龄中位数39.5岁,平均病程(15.1±5.0)年.14例患者曾接受其他生物制剂治疗至少4个月,但未达到银屑病皮损面积严重度指数(PASI)75,或在治疗过程中失去了PASI 75.观察在接受古塞奇尤单抗注射液治疗12周及20周时的疗效及不良反应.结果 14例患者给予古塞奇尤单抗注射液治疗12周后,PASI评分从基线时(8.0±3.5)分下降至(1.7±1.4)分,PASI 75/90应答率分别为85.7％及 35.7％;20 周时 PASI 评分为(0.93±0.81)分,PASI 75/90/100 应答率分别为 100％、57.1％、7.1％.1例患者出现疲劳(7.14％),2例患者出现上呼吸道感染(14.29％).结论 应用古塞奇尤单抗注射液治疗其他生物制剂应答不佳的中重度斑块状银屑病患者可以取得明显疗效,且未观察到严重不良反应.
Abstract
Objective To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis who exhibited inadequate response to other biologics.Methods A total of 14 patients were enrolled,including 9 males and 5 females,with a median age of 39.5 years and an average disease duration of(15.1±5.0)years.All patients previously undergone treatment with other biologics for at least 4 months,yet failed to achieve achieved psoriasis area and severity index(PASI)75 or lost PASI 75 during treatment.After switching to guselkumab treatment,the efficacy and adverse reactions of these patients were assessed at week 12 and week 20.Results After 12 weeks of treatment with guselkumab,the mean PASI score of 14 patients decreased from 8.0±3.6 at baseline to 1.7±1.4,with PASI 75/90 response rates of 85.7％and 35.7％,respectively.At week 20,the mean PASI score were 0.93±0.81,and the PASI75/90/100 response rate were 100％,57.1％and 7.1％,respectively.Fatigue was reported in 1 patient(7.14％),while two patients(14.29％)experienced upper respiratory tract infection.Conclusion Guselkumab showed significant efficacy in patients with moderate-to-severe plaque psoriasis who exhibited inadequate response to other biologics,while no serious adverse reactions were observed.
关键词
银屑病/古塞奇尤单抗/生物制剂/白细胞介素23Key words
Psoriasis/Guselkumab/Biological agents/interleukin-23引用本文复制引用
基金项目
江苏省中医药科技发展计划项目(MS2021099)
苏州大学附属第一医院博习临床研究项目(BXLC018)
出版年
2024
NETL
NSTL
万方数据